Literature DB >> 18579697

Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin-producing Escherichia coli in travelers from the United States who are visiting Mexico.

Jose Flores1, Herbert L DuPont, Stephanie A Lee, Jaime Belkind-Gerson, Mercedes Paredes, Jamal A Mohamed, Lisa Y Armitige, Dong-Chuan Guo, Pablo C Okhuysen.   

Abstract

Up to 60% of U.S. visitors to Mexico develop traveler's diarrhea (TD), mostly due to enterotoxigenic Escherichia coli (ETEC) strains that produce heat-labile (LT) and/or heat-stable (ST) enterotoxins. Distinct single-nucleotide polymorphisms (SNPs) within the interleukin-10 (IL-10) promoter have been associated with high, intermediate, or low production of IL-10. We conducted a prospective study to investigate the association of SNPs in the IL-10 promoter and the occurrence of TD in ETEC LT-exposed travelers. Sera from U.S. travelers to Mexico collected on arrival and departure were studied for ETEC LT seroconversion by using cholera toxin as the antigen. Pyrosequencing was performed to genotype IL-10 SNPs. Stools from subjects who developed diarrhea were also studied for other enteropathogens. One hundred twenty-one of 569 (21.3%) travelers seroconverted to ETEC LT, and among them 75 (62%) developed diarrhea. Symptomatic seroconversion was more commonly seen in subjects who carried a genotype producing high levels of IL-10; it was seen in 83% of subjects with the GG genotype versus 54% of subjects with the AA genotype at IL-10 gene position -1082 (P, 0.02), in 71% of those with the CC genotype versus 33% of those with the TT genotype at position -819 (P, 0.005), and in 71% of those with the CC genotype versus 38% of those with the AA genotype at position -592 (P, 0.02). Travelers with the GCC haplotype were more likely to have symptomatic seroconversion than those with the ATA haplotype (71% versus 38%; P, 0.002). Travelers genetically predisposed to produce high levels of IL-10 were more likely to experience symptomatic ETEC TD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579697      PMCID: PMC2519301          DOI: 10.1128/CVI.00070-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Risk and aetiology of diarrhoea at various tourist destinations.

Authors:  F von Sonnenburg; N Tornieporth; P Waiyaki; B Lowe; L F Peruski; H L DuPont; J J Mathewson; R Steffen
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

2.  Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico.

Authors:  Alain R Bouckenooghe; Zhi Dong Jiang; Francisco J De La Cabada; Charles D Ericsson; Herbert L DuPont
Journal:  J Travel Med       Date:  2002 May-Jun       Impact factor: 8.490

Review 3.  Epidemiology of traveler's diarrhea.

Authors:  Robert Steffen
Journal:  Clin Infect Dis       Date:  2005-12-01       Impact factor: 9.079

4.  Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico.

Authors:  GwangPyo Ko; Coralith Garcia; Zhi-Dong Jiang; Pablo C Okhuysen; Jaime Belkind-Gerson; Roger I Glass; Herbert L DuPont
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis.

Authors:  Juan Sainz; Laila Hassan; Eva Perez; Antonio Romero; Antonio Moratalla; Elisa López-Fernández; Salvador Oyonarte; Manuel Jurado
Journal:  Immunol Lett       Date:  2007-02-08       Impact factor: 3.685

6.  Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico.

Authors:  Javier A Adachi; Charles D Ericsson; Zhi-Dong Jiang; Margaret W DuPont; Sanjay R Pallegar; Herbert L DuPont
Journal:  J Infect Dis       Date:  2002-05-17       Impact factor: 5.226

7.  Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study.

Authors:  S Sinha; K N Prasad; D Jain; C M Pandey; S Jha; S Pradhan
Journal:  Clin Microbiol Infect       Date:  2007-03       Impact factor: 8.067

8.  Seroepidemiologic evaluation of anti-toxic and anti-colonization factor immunity against infections by LT-producing Escherichia coli in rural Bangladesh.

Authors:  J D Clemens; A M Svennerholm; J R Harris; S Huda; M Rao; P K Neogy; M R Khan; M Ansaruzzaman; S Rahaman; F Ahmed
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

9.  Single multiplex polymerase chain reaction to detect diverse loci associated with diarrheagenic Escherichia coli.

Authors:  Catalina López-Saucedo; Jorge F Cerna; Nicolas Villegas-Sepulveda; Rocío Thompson; F Raul Velazquez; Javier Torres; Phillip I Tarr; Teresa Estrada-García
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

10.  Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method.

Authors:  John Clemens; Stephen Savarino; Remon Abu-Elyazeed; Mohammad Safwat; Malla Rao; Thomas Wierzba; Ann-Marie Svennerholm; Jan Holmgren; Robert Frenck; Eunsik Park; Abdollah Naficy
Journal:  J Infect Dis       Date:  2004-05-25       Impact factor: 5.226

View more
  12 in total

Review 1.  Genetics of susceptibility to infection with enteric pathogens.

Authors:  Jose Flores; Pablo C Okhuysen
Journal:  Curr Opin Infect Dis       Date:  2009-10       Impact factor: 4.915

2.  Pilot study of whole-blood gamma interferon response to the Vibrio cholerae toxin B subunit and resistance to enterotoxigenic Escherichia coli-associated diarrhea.

Authors:  Jose Flores; Herbert L DuPont; Mercedes Paredes-Paredes; M Magdalena Aguirre-Garcia; Araceli Rojas; Alexei Gonzalez; Pablo C Okhuysen
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

Review 3.  Food poisoning and diarrhea: small intestine effects.

Authors:  John R Cangemi
Journal:  Curr Gastroenterol Rep       Date:  2011-10

Review 4.  Enterobacteria and host resistance to infection.

Authors:  Eugene Kang; Alanna Crouse; Lucie Chevallier; Stéphanie M Pontier; Ashwag Alzahrani; Navoun Silué; François-Xavier Campbell-Valois; Xavier Montagutelli; Samantha Gruenheid; Danielle Malo
Journal:  Mamm Genome       Date:  2018-05-21       Impact factor: 2.957

Review 5.  [Genetic susceptibility to infections].

Authors:  S J Ott; S Schreiber
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

6.  Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico.

Authors:  Jamal A Mohamed; Herbert L DuPont; Jose Flores; Himaja Palur; Parvathy Nair; Zhi-Dong Jiang; Dongchuan Guo; Jaime Belkind-Gerson; Pablo C Okhuysen
Journal:  Clin Infect Dis       Date:  2011-06       Impact factor: 9.079

7.  New Developments in Traveler's Diarrhea.

Authors:  Javier de la Cabada Bauche; Herbert L Dupont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

8.  Association of diarrheagenic Escherichia coli Pathotypes with infection and diarrhea among Mexican children and association of atypical Enteropathogenic E. coli with acute diarrhea.

Authors:  Teresa Estrada-Garcia; Catalina Lopez-Saucedo; Rocio Thompson-Bonilla; Maricela Abonce; Daniel Lopez-Hernandez; Jose Ignacio Santos; Jorge L Rosado; Herbert L DuPont; Kurt Z Long
Journal:  J Clin Microbiol       Date:  2008-11-19       Impact factor: 5.948

9.  Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections.

Authors:  Kurt Z Long; Jorge L Rosado; José Ignacio Santos; Meredith Haas; Abdullah Al Mamun; Herbert L DuPont; Nanda N Nanthakumar; Teresa Estrada-Garcia
Journal:  Infect Immun       Date:  2009-12-28       Impact factor: 3.441

Review 10.  Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines.

Authors:  Gregory M Glenn; David H Francis; E Michael Danielsen
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.